Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The marine ecosystem that has contributed to the discovery of cytarabine and its fluorinated derivative gemcitabine is now considered the most productive toll to acquire new natural derived anticancer entities. Few marine anticancer agents have entered clinical development, including bryostatin-1, dolastatin 10, LU103793, ET-743, kahalalide F, didemnin B and aplidine. The marine plitidepsin aplidine derived from the mediterranean tunicate Aplidium albicans is a synthetically produced anticancer agent that is structurally related to didemnins. Aplidine's mechanism of action involves several pathways, including cell cycle arrest, inhibition of protein synthesis and antiangiogenic activity. Phase I studies have been reported for a number of several schedules including 1-hour, 3-hour and 24-hour infusion. Evidences of antitumor activity and clinical benefit of aplidine in several tumor types were noted across phase I trials, particularly in advanced medullar thyroid carcinoma. Phase II studies are underway. Within the entire phase I program, dose-limiting toxicities of aplidine were neuromuscular toxicity, asthenia, skin toxicity, and diarrhea. Interestingly, no hematological toxicity was observed. Aplidine displayed a very peculiar delayed neuromuscular toxicity that was found to be closely related to the symptoms described in the adult form of carnitine palmitoyl transferase deficiency type 2, which is a genetic disease treated with L-carnitine. Consistently, concomitant administration of L-carnitine allowed to improve aplidine-induce neuromuscular toxicity. In summary, aplidine is a novel marine anticancer agent with a very particular delayed neuromuscular toxicity that requires careful follow-up with promising antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the period 1981–2002
Newman, D. J., Cragg, G. M., & Snader, K. M. (2003) · Journal of Natural Products · doi:10.1021/np030096l · Cited by 3,082 · cited 1×
“For many years, screening of large libraries of molecules from animals, plants, and microorganisms with antiproliferative properties against cell lines made Nature the primary source of an unlimited number of anticancer agents with complex chemical structures including vinca alkaloids, taxanes, camptothecin derivative…”
BackgroundThe Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“This transport involves 3 enzymes located in outer and inner leaflets of mitochondrial membranes [143]:”
Background
Cited by
Impact of Natural Products on Developing New Anti-Cancer Agents
Cragg, G. M., Grothaus, P. G., & Newman, D. J. (2009) · Chemical Reviews · doi:10.1021/cr900019j · Cited by 1,302
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Blunt, J. W., Copp, B. R., Hu, W.-P., Munro, M. H. G., Northcote, P. T., & Prinsep, M. R. (2009) · Natural Product Reports · doi:10.1039/b805113p · Cited by 520
Anticancer Activity of Natural Compounds from Plant and Marine Environment
Lichota, A., & Gwozdzinski, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113533 · Cited by 473
Metadata
- Authors
- Tourneau, C., Raymond, E., & Faivre, S.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-11-01
- Volume
- 13
- Issue
- 33
- Pages
- 3427-3439
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2157202197
- Cited by
- 56
- References
- 2
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison. https://app.cochat.ai/papers/10.2174/138161207782360555
- The paper
- Tourneau, C., Raymond, E., & Faivre, S. (2007). Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison. Current Pharmaceutical Design. https://doi.org/10.2174/138161207782360555
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.